Relay Therapeutics
RLAY · NASDAQ
$18.45+$1.36 (+7.96%)TodayMarket closed ·
Prev close $17.09
EPS: actual vs estimate
Beat the estimate in 5 of the last 8 quarters, by 17.8% on average
Next report: , after the market closes
- Quarter
- Q3 FY26
- EPS estimate
- -$0.40
- Revenue estimate
- $1.45M
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | -$0.3989 | -$0.41 | −2.8% |
| Q1 FY26 | -$0.3844 | -$0.41 | −6.7% |
| Q4 FY25 | -$0.4124 | -$0.32 | +22.4% |
| Q3 FY25 | -$0.4238 | -$0.43 | −1.5% |
| Q2 FY25 | -$0.5014 | -$0.41 | +18.2% |
| Q1 FY25 | -$0.4978 | -$0.46 | +7.6% |
| Q4 FY24 | -$0.573 | -$0.45 | +21.5% |
| Q3 FY24 | -$0.7829 | -$0.63 | +19.5% |
Earnings calls
- Morgan Stanley 24th Annual Global Healthcare Conference
- Wells Fargo 21st Annual Healthcare Conference
- Goldman Sachs 47th Annual Global Healthcare Conference 2026
- Jefferies Global Healthcare Conference 2026
- Special Call - Relay Therapeutics, Inc.
- Special Call - Relay Therapeutics, Inc.
- Special Call - Relay Therapeutics, Inc.
- Barclays 28th Annual Global Healthcare Conference
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.